Trajan Scientific and Medical (Trajan) is now offering clinical diagnostic packing, a reliable outsourced packing solution for hospitals and pathology clinics, enabling them to focus on core business activities, maximizing diagnostic testing revenue and ultimately improving patient care.
With over 30 years experience in pathology supply in Australia and New Zealand, a global supply network, and clean manufacturing facilities, Trajan is well placed to provide a complete end-to-end solution based at newly renovated facilities within Trajan’s Global Corporate Headquarters located in Melbourne, Australia.
Trajan identified the need for a complete packing solution, due to recent changes in 2015 to the Australian Therapeutic Goods Administration (TGA) In-vitro Diagnostic Framework requirements for registration of products used in clinical applications.
By working closely with the Australian diagnostic community to improve this part of their operations, Trajan creates TGA-compliant procedure packs tailored for a range of clinical applications.
Mr David Giddens, Operations Manager, Clinical Diagnostic Packing, says Trajan’s custom procedure packs contain all items in one convenient pack for clinical procedures, they save time for clinicians and is less invasive for patients.
“Using ready-made packs minimizes contamination of contents and facilitates the process of sending samples to the laboratory, improving turnaround times for patient results.” said Mr Giddens.
Chief Executive Officer of Trajan, Mr Stephen Tomisich is keen to develop the company’s capabilities in this medical field, saying it is a logical step while collaborating with healthcare partners.
“This takes us closer to patients and increases the number of roles Trajan can play in making a positive impact on human wellbeing.” said Mr Tomisich.
Photo: Mr David Giddens, Operations Manager, Clinical Diagnostic Packing, at the newly renovated facilities at Trajan Scientific and Medical in Melbourne, Australia.
Clinical Diagnostic Packing
In response to the COVID-19 pandemic, the biopharmaceutical industry has leapt into action to better understand the disease and develop suitable vaccines and therapies.
Trajan Scientific and Medical and Synexa Life Sciences have developed and validated an innovative, market-leading SARS-CoV-2 serology assay, available for high-throughput clinical research applications, using Trajan's advanced precision microsampling technology to expedite therapy and vaccine development as well as large-scale screening, sero-surveillance and post-market surveillance initiatives.
Trajan Scientific and Medical’s hemaPEN® microsampling technology has been developed with extensive consultation and evaluation by leading analytical laboratories, clinicians and healthcare professionals.
This month, Trajan presents an exclusive interview with researcher Dr Michele Protti of Pharmaco-Toxicological Analysis, Bologna, Italy, on the future of microsampling and the critical role hemaPEN can play when used in therapeutic drug monitoring for optimal therapy personalization.